PDCD1LG2 and cancer: There is a growing consensus that immune checkpoint inhibitors can synergize with chemotherapy in many solid tumors.32,33 Although the interactions between PD-L2 markers in ER+ tumors and other clinicopathological covariates were not statistically significant, the interaction between chemotherapy and high cancer cell PD-L2 was potentially important (HR, 1.9; 95% CI, 0.9 to 4.0; P = .091).